Objectives: Streptococcus pyogenes causes various diseases in humans. While the prevalence of fluoroquinolone-resistant S. pyogenes isolates has been increasing since 2000 in the USA and Europe, it has remained very low in Japan. We isolated a fluoroquinolone-resistant S. pyogenes strain and analysed its genetics.
Introduction
Streptococcus pyogenes causes pharyngitis, scarlet fever and severe infections such as streptococcal toxic shock syndrome and necrotizing fasciitis. This organism has many pathogenic features, such as adherence to epithelial cells, the ability to invade tissues and the ability to produce extracellular virulence factors, including streptococcal pyogenic exotoxins (SpeA, SpeB and SpeC) and streptolysin O. S. pyogenes possesses M-, R-and T-proteins on its outer membrane. M-protein is related to thermostability, anti-opsonin activity, adherence to epithelial cells and other virulence features, with .100 types having been found.
Fluoroquinolone resistance in S. pyogenes is caused by amino acid substitutions in four polypeptides called GyrA, GyrB, ParC and ParE, which are respectively coded for by at least one point mutation in the genes gyrA, gyrB, parC and parE located in the quinolone resistance-determining region (QRDR). The genes gyrA and gyrB code for DNA gyrase (topoisomerase II) subunits A and B, while parC and parE code for topoisomerase IV subunits C and E.
In 2000, the first fluoroquinolone-resistant S. pyogenes was reported by Yan et al. in the USA. 1 Following this, reports of such isolates from other parts of the USA and Europe have gradually been increasing. 2 -4 In contrast, reports of fluoroquinoloneresistant S. pyogenes from Japan have been rare. We recently found a levofloxacin-resistant (MIC 16 mg/L) clinical isolate of S. pyogenes at Tohoku University Hospital in Japan. In the present study, we examined the molecular features of its resistance mechanism.
Materials and methods

Bacterial isolate
When a patient in their thirties was diagnosed as having pharyngitis in autumn 2007, a throat swab was taken for bacterial testing. S. pyogenes was isolated from the specimen and was found to be resistant to levofloxacin with an MIC of 16 mg/L. The patient was treated with amoxicillin, and subsequently the infection by S. pyogenes was cleared. The patient had been hospitalized repeatedly and had received various antimicrobial agents, including fluoroquinolones.
The isolate, S. pyogenes TU-296, was stored at 2808C and was cultured on 5% sheep blood agar at 358C for 20 h under 5% CO 2 .
Antimicrobial susceptibility testing
The MICs of antimicrobial agents were determined by the microdilution method according to the recommendations of the CLSI (2009). Streptococcus pneumoniae ATCC 49619 was used for quality control. The quinolones tested were norfloxacin (KYORIN Pharmaceutical Co. Ltd, Tokyo, Japan), ofloxacin, levofloxacin and nalidixic acid (Daiichi-Sankyo Co. Ltd, Tokyo, Japan), enoxacin and sparfloxacin (Dainippon Sumitomo Pharma, Tokyo, Japan), ciprofloxacin, lomefloxacin and cinoxacin (Sigma-Aldrich Japan K.K., Tokyo, Japan), prulifloxacin (Meiji Seika Kaisha Ltd, Tokyo, Japan), moxifloxacin (Bayer Health Care, Berlin, Germany) and garenoxacin (Taisyo Toyama Pharmaceutical Co. Ltd, Tokyo, Japan). The MICs of these antimicrobial agents were determined by using a microdilution method. The MIC of gatifloxacin was measured at BML Co. Ltd (Saitama, Japan), while the MICs of erythromycin, clarithromycin, azithromycin, josamycin, clindamycin, quinupristin/dalfopristin, telithromycin, penicillin, cefotaxime, cefepime and meropenem were measured using Eiken dry plates (Eiken Chemical Co. Ltd, Tokyo, Japan).
DNA extraction from an isolate
Aliquots of sterile distilled water (100 mL) were dispensed into 0.2 mL microtubes. A few colonies of S. pyogenes TU-296 were suspended in the water and heated for 10 min at 958C in a thermal cycler, cooled on crushed ice and centrifuged at 15 000 rpm for 1 min. Then the supernatant was used as a DNA template.
PCR amplification of gyrA, gyrB, parC and parE in the QRDR and the emm gene Amplification of the gyrA, gyrB, parC and parE genes in the QRDR was performed by PCR using primer sets described previously.
1 Amplification was performed for 30 cycles, each cycle consisting of pre-heating at 948C for 10 min, denaturation at 948C for 1 min, annealing at 618C for 1 min (for gyrA, parC and parE) or at 668C for 1 min (for gyrB) and extension at 728C for 1 min, followed by an additional extension at 728C for 10 min.
The emm gene encoding M-protein was analysed by PCR according to a modified protocol of the CDC (http://www.cdc.gov/ncidod/biotech/ strep/protocol_ emm-type.htm). Amplification of the emm gene was performed for 30 cycles, each cycle consisting of pre-heating at 948C for 10 min, denaturation at 948C for 1 min, annealing at 528C for 1 min and extension at 728C for 1 min, followed by an additional extension at 728C for 10 min. The PCR products were confirmed to be a single band by mini-submarine electrophoresis.
DNA sequencing
The PCR products were purified with a QIAquick w PCR purification kit (Qiagen GmbH, Germany), according to the manufacturer's instructions. DNA sequencing of the purified products (gyrA, gyrB, parC, parE and emm) was carried out with a Big Dye w Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems Company Ltd, CA, USA) in an ABI 3730xl Genetic Analyzer (Applied Biosystems), according to the manufacturer's instructions.
Analysis of data
The data obtained by DNA sequencing were compared with the QRDR of the genomes of various bacteria by the BLAST program (http://blast.ncbi. nlm.nih.gov/Blast.cgi). emm typing was performed with the online CDC emm database (http://www.cdc.gov/ncidod/biotech/strept/strepblast. htm). Finally, each sequence of gyrA and parC was compared with those of GenBank accession nos. AF220945 and AF220946 for gyrA and parC, respectively, of fluoroquinolone-susceptible S. pyogenes ATCC 700294.
Sequences of parC and parE in S. pyogenes TU-296 were analysed by the ClustalW program and Tree View X.
Results
The MICs of nalidixic acid and cinoxacin were 256 and 512 mg/L, respectively; the MICs of norfloxacin, ofloxacin and enoxacin were 32, 16 and 32 mg/L, respectively; the MICs of levofloxacin, lomefloxacin and sparfloxacin were 16-64 mg/L; and the MICs of prulifloxacin, moxifloxacin, gatifloxacin and garenoxacin were 0.25 -4 mg/L. Garenoxacin had the lowest MIC of 0.25 mg/L among the quinolones. Macrolide, lincosamide, streptogramin, ketolide and b-lactam antibiotics were active against this isolate. The quinupristin/dalfopristin combination showed intermediate activity.
A base substitution (cytosine for adenine at position 476) was found in the partial sequence of gyrA in S. pyogenes TU-296 (accession no. AB514146), resulting in substitution of alanine (GCA) for glutamic acid (GAA) at position 85 (Glu-85 Ala) in GyrA. Another base substitution (thymine for cytosine at position 367) was found in the partial sequence of parC (DDBJ accession no. AB518044), resulting in substitution of phenylalanine (TTC) for serine (TCC) at position 79 (Ser-79 Phe) in ParC. The sequences of parC and parE from S. pyogenes TU-296 showed high homology with Streptococcus dysgalactiae subsp. equisimilis according to the bits score, E-value, phylogenetic tree with the ClustalW program and TreeView X (see Figure 1) .
The genotype of the M-protein of S. pyogenes TU-296 was determined as emm11 by comparison with the CDC emm database. Table 1 summarizes previous reports of amino acid substitutions attributed to point mutations in the QRDR of gyrA and parC and the susceptibility profile of S. pyogenes TU-296 to various quinolones in the present study. Reports on surveillance performed in Spain, 6 Belgium 7 and the USA 8 are indicated in the last three rows of the table. Our new strain occupies an intermediate position on the scale of resistance to fluoroquinolones, and we suspect that the cause of resistance is the substitution Glu-85 Ala in GyrA. 
GBS, GTC1966, pc Sp, GTC543, pc Su, 0140J, cg GAS, MGAS8232, cg GAS, pc GAS, pc GAS, pc GAS, MGAS10394, cg GAS, strain 4302, pc GAS, pc GAS, MGAS10750, cg GAS, MGAS10270, cg GAS, MGAS6180, cg GAS, MGAS2096, cg GAS, MGAS9429, cg GAS, Manfredo, cg GAS, NZ131, cg GAS, SSI-1, cg GAS, pc GGS, M23, pc GGS, M22, pc GGS M12, pc AB518044, GAS, TU-296, pc GGS, M15, pc GAS, strain NIH-R01-GAS, pc GGS, M1, pc 0.1 GBS, GTC1967, pc Figure 1 . Phylogenetic tree analysis of parC in the QRDR of S. pyogenes TU-296 and other streptococci. The parC sequence of fluoroquinolone-resistant S. pyogenes TU-296 with substitution of Ser-79 Phe (DDBJ accession no. AB518044) was compared with that of parC in other streptococci by ClustalW and BLAST. TU-296 was isolated at Tohoku University Hospital, Japan. The figure shows part of the phylogenetic tree for parC. This figure was adapted from the phylogenetic tree created by TreeView X. Evolutionary distances were computed by the Kimura 2 parameter method. GBS, S. agalactiae; GAS, S. pyogenes; GGS, S. dysgalactiae subsp. equisimilis; Sp, Streptococcus porcinus; Su, Streptococcus uberis; pc, partial code; cg, complete genome. 1 -10 However, the substitution Glu-85 Ala in GyrA of our fluoroquinolone-resistant S. pyogenes TU-296 (DDBJ accession no. AB514146) has not been reported previously. Substitution of Glu-85 with Lys or Gly in GyrA of S. pyogenes was reported as resulting in a stepwise increase in the MIC of quinolones in an experimental study. Substitution of Glu-85 Lys and Gly in GyrA of S. pneumoniae and Streptococcus agalactiae was found in clinical isolates. Substitution of Glu-85 Ala in S. pneumoniae selected experimentally by gemifloxacin has also been reported, and the S. pneumoniae was not a clinical isolate. To our knowledge, however, the substitution Glu-85 Ala in a fluoroquinolone-resistant S. pyogenes has not been previously reported in a clinical isolate.
The sequences of parC (DDBJ accession no. AB518044) and parE in S. pyogenes TU-296 revealed many point mutations, and were homologous with S. dysgalactiae subsp. equisimilis, showing a high bits score and a low E-value by cluster analysis. Similar cases have been reported previously. In Japan, the frequency of fluoroquinolone-resistant S. pyogenes clinical isolates has been extremely low compared with that in the USA and Europe. According to a previous report 5 from Japan, the amino acid substitutions detected were Ser-81 Phe in GyrA and Ser-79 Phe in ParC. This finding was similar to reports from the USA and Europe.
In conclusion, we report the first S. pyogenes clinical isolate with substitution of Glu-85 Ala in GyrA. Amino acid substitutions in GyrA and ParC of S. pyogenes strains showing an MIC of levofloxacin of 2 or 4 mg/L have been reported previously. We need to carefully monitor the prevalence of fluoroquinolone resistance among clinical isolates of S. pyogenes in the future.
